October 21, 2019What's New
One of the features in ON TARGET this week is Huntington's disease (HD), a rare and devastating disease. Target Health received feedback from FDA on a program in HD and we all look forward to a successful outcome. Target Health is currently very active in the rare and orphan disease space with 2 new orphan disease designations granted by FDA this month. In addition, a meeting was held last week with FDA to discuss a novel approach for a rare disease and another meeting with FDA for a very rare disease will take place next month. A phase 1 study is also underway which will support the phase 2 program in a rare neurological disease.
For more information about Target Health, contact Warren Pearlson (212-681-2100 ext. 165). For additional information about software tools for paperless clinical trials, please also feel free to contact Dr. Jules T. Mitchel. The Target Health software tools are designed to partner with both CROs and Sponsors. Also visit the Target Health Eating Website to see all of the fantastic recipes since 2012.
Joyce Hays, Founder and Editor in Chief of On Target
Dr. Jules T. Mitchel, Editor